Published in J Manag Care Pharm on October 01, 2011
What's fueling the biotech engine--2010 to 2011. Nat Biotechnol (2011) 1.17
Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev (2012) 1.15
Skeletal metastasis: treatments, mouse models, and the Wnt signaling. Chin J Cancer (2013) 0.95
Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. Support Care Cancer (2012) 0.82
Management of bone metastases in refractory prostate cancer--role of denosumab. Clin Interv Aging (2012) 0.80
Chemotherapy- and irradiation-induced bone loss in adults with solid tumors. Curr Osteoporos Rep (2015) 0.79
Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer. Asian J Androl (2014) 0.79
Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients. J Craniomaxillofac Surg (2015) 0.78
Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences. J Bone Oncol (2012) 0.76
Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases. Support Care Cancer (2013) 0.76
Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. Anticancer Res (2012) 0.75
US-Based Drug Cost Parameter Estimation for Economic Evaluations. Med Decis Making (2014) 0.75
Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm (2012) 0.75
Thiocolchicoside a semi-synthetic derivative of the Glory Lily: a new weapon to fight metastatic bone resorption? Br J Pharmacol (2012) 0.75
Words of wisdom. Re: Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. Eur Urol (2012) 0.75
Clinical efficacy of denosumab versus bisphosphonates for the prevention of bone complications: implications for nursing. Support Care Cancer (2015) 0.75
Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol (2010) 2.93
Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy (2012) 2.06
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ (2012) 2.05
The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry (2005) 2.03
Annual costs associated with diagnosis of uterine leiomyomata. Obstet Gynecol (2006) 1.96
Human IgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem (2008) 1.88
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology (2008) 1.78
Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. Ann Pharmacother (2011) 1.51
Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis. Curr Med Res Opin (2012) 1.46
Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm (2008) 1.42
Health-related quality of life predicts outcomes but is not affected by peritoneal clearance: The ADEMEX trial. Kidney Int (2005) 1.40
Patient-reported health status in coronary heart disease in the United States: age, sex, racial, and ethnic differences. Circulation (2008) 1.39
Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. Value Health (2005) 1.32
Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients. Kidney Int (2005) 1.30
Direct and indirect costs among employees with diabetic retinopathy in the United States. Curr Med Res Opin (2008) 1.28
Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S. Obesity (Silver Spring) (2007) 1.28
Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States. Stroke (2006) 1.24
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol (2008) 1.21
Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ (2011) 1.19
Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics (2010) 1.10
Increased risks of developing anxiety and depression in young patients with Crohn's disease. Am J Gastroenterol (2011) 1.10
Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ (2011) 1.10
Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke from the hospitals' perspectives. Circ Cardiovasc Qual Outcomes (2012) 1.09
Productivity costs associated with cardiometabolic risk factor clusters in the United States. Value Health (2007) 1.08
Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med (2012) 1.08
Re.: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ (2012) 1.07
Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment. J Manag Care Spec Pharm (2015) 1.06
Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol (2009) 1.05
Disulfide connectivity of human immunoglobulin G2 structural isoforms. Biochemistry (2008) 1.05
Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health (2012) 1.03
Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther (2009) 1.02
Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin (2010) 1.01
Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther (2012) 1.01
Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin (2007) 1.01
Burden of premenstrual dysphoric disorder on health-related quality of life. J Womens Health (Larchmt) (2008) 1.00
Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin (2010) 0.99
Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol (2011) 0.99
Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin (2009) 0.98
Adherence to inhaled corticosteroid use and local adverse events in persistent asthma. Am J Manag Care (2008) 0.97
Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. J Am Coll Radiol (2009) 0.96
Bile acid binding to sevelamer HCl. Kidney Int (2002) 0.96
Fluorescent derivatization method of proteins for characterization by capillary electrophoresis-sodium dodecyl sulfate with laser-induced fluorescence detection. Anal Chem (2007) 0.95
Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010). Curr Med Res Opin (2014) 0.95
Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am J Ther (2012) 0.94
Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin (2009) 0.94
Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need. Transfusion (2012) 0.94
Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med (2010) 0.93
Clinical outcomes and medical care costs among medicare beneficiaries receiving therapy for peripheral arterial disease. Ann Vasc Surg (2010) 0.93
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. Clin Drug Investig (2011) 0.92
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Curr Med Res Opin (2011) 0.92
The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol (2010) 0.92
Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis. Clin Breast Cancer (2011) 0.90
Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol (2009) 0.90
Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med (2011) 0.90
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol (2011) 0.90
Development and validation of the Premenstrual Symptoms Impact Survey (PMSIS): a disease-specific quality of life assessment tool. J Womens Health (Larchmt) (2008) 0.89
Cost-effectiveness of treatments for dysfunctional uterine bleeding in women who need contraception. Contraception (2006) 0.89
Interchain disulfide bonding in human IgG2 antibodies probed by site-directed mutagenesis. Biochemistry (2009) 0.89
Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. Curr Med Res Opin (2013) 0.89
The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol (2011) 0.89
Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population. J Occup Environ Med (2006) 0.88
Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin (2010) 0.88
Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer (2012) 0.88
Costs of Parkinson's disease in a privately insured population. Pharmacoeconomics (2013) 0.87
Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia. J Pain (2009) 0.87
Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Pharmacoepidemiol Drug Saf (2012) 0.86
Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Curr Med Res Opin (2014) 0.86
Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis. Diabetes Res Clin Pract (2009) 0.86
Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol (2012) 0.85
Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Eur J Gastroenterol Hepatol (2009) 0.85
Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin (2010) 0.85
Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. J Med Econ (2015) 0.85
Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis. J Med Econ (2013) 0.84
Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy. Int J Cardiol (2012) 0.83
Development and validation of a claims-based prediction model for COPD severity. Respir Med (2013) 0.83
Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. Curr Med Res Opin (2008) 0.83
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia. J Med Econ (2013) 0.82
Use of inhaled corticosteroids and healthcare costs in mild persistent asthma. J Asthma (2007) 0.82
Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis. J Med Econ (2014) 0.82
Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change. J Clin Psychiatry (2011) 0.82
Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes. Diabetes Care (2013) 0.82